Extensively Drug-resistant Tuberculosis
📧 Sign up to get email alerts when something new happens for Extensively Drug-resistant Tuberculosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-06Clinical Trial Results: TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB [Phase 1, Phase 2]
Clinical trial results report on safety and tolerability of low-dose linezolid in multi-drug resistant and extensively drug-resistant tuberc…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Training Protocol on the Natural History of Tuberculosis
Sponsored by NIAID, this ClinicalTrials.gov entry outlines a training protocol to study the natural history of tuberculosis, including laten…
-
CLINICAL_TRIALS trial_result · 2025-06-26Clinical Trial Update: Triage Test for All Oral DR-TB Regimen (TRiAD Study)
A completed clinical trial update on the TRiAD study evaluating a triage diagnostic test for all-oral regimens in drug-resistant tuberculosi…
-
CLINICAL_TRIALS trial_result · 2025-04-24Clinical Trial Update: TBTC Study 30: Safety and Tolerability of Low Dose Linezolid in MDR TB [Phase 1, Phase 2]
This trial update reports on the safety and tolerability of low-dose Linezolid in patients with multidrug-resistant and extensively drug-res…
-
FDA approval · 2024-11-22FDA Approved: PRETOMANID — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Pretomanid submitted by Viatris Specialty LLC, updating its labeling to reflect its use in drug-…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-08-28Clinical Trial Update: Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care [Phase 3]
Phase 3 trial evaluating a short-course regimen containing bedaquiline, delamanid, and linezolid versus the current standard of care for rif…
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) [Phase 2, Phase 3]
This document reports an update on a pragmatic Phase 2/3 trial evaluating a more effective, concise, and less toxic regimen for multidrug-re…
-
CLINICAL_TRIALS research · 2024-04-22Clinical Trial Update: Economic Evaluation of New MDR TB Regimens [Phase 2, Phase 3]
A clinical trial update evaluating the economic aspects of new regimens for multidrug-resistant and extensively drug-resistant tuberculosis …
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis [Phase 3]
Phase 3 trial evaluating various doses and durations of a regimen including linezolid with bedaquiline and pretomanid for drug-resistant tub…
-
FDA approval · 2022-12-21FDA Approved: PRETOMANID — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Pretomanid, submitted by Viatris Specialty LLC.
-
CLINICAL_TRIALS trial_result · 2021-12-01Clinical Trial Update: A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) [Phase 2]
Phase 2 trial update for OPC 67683 in pulmonary sputum culture-positive, multidrug-resistant tuberculosis (TB) has completed with results po…
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis [Phase 2, Phase 3]
An open-label randomized trial evaluated a new treatment regimen for patients with multi-drug resistant tuberculosis, including phase 2 and …
-
CLINICAL_TRIALS trial_result · 2021-05-14Clinical Trial Update: PRACTECAL-PKPD Sub Study [Phase 2, Phase 3]
Phase 2/3 trial update for the PRACTECAL-PKPD Sub Study investigating treatment regimens for drug-resistant tuberculosis.
-
FDA approval · 2019-08-14FDA Approved: PRETOMANID — Original Application (Viatris Specialty LLC)
FDA approved pretomanid under NDA 212862 from Viatris Specialty LLC. The approval addresses treatment options for drug-resistant tuberculosi…
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Tuberculosis in China
This entry notes the completion of a National Institute of Allergy and Infectious Diseases study conducted in China focused on tuberculosis.…
-
CLINICAL_TRIALS trial_result · 2018-04-05Clinical Trial Update: Utility of MODS for Diagnosis of MDR-TB and Second-Line Antituberculous Drug Susceptibility Testing in Mali
The terminated trial assessed the MODS test for diagnosis of multidrug-resistant tuberculosis and for second-line antituberculous drug susce…
-
CLINICAL_TRIALS approval · 2017-11-27Clinical Trial Update: Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
The document notes marketing approval for TMC207 (bedaquiline) to treat extensively drug-resistant or pre-XDR pulmonary tuberculosis through…
-
CLINICAL_TRIALS trial_result · 2014-02-24Clinical Trial Update: Linezolid to Treat Extensively-Drug Resistant Tuberculosis [Phase 2]
A Phase 2 trial evaluating linezolid for extensively drug-resistant tuberculosis has completed, with results posted in 2014. The study encom…
-
CLINICAL_TRIALS trial_result · 2013-07-01Clinical Trial Update: Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients [Phase 4]
A Phase 4 drug interaction study assessed the combination of linezolid and clarithromycin in patients with multidrug-resistant tuberculosis …